TRVI Stock Forecast & Price Target

Trevi Therapeutics is fundamentally attractive because Haduvio has already shown differentiated efficacy in Phase 2a RIVER, with a 57% placebo-adjusted reduction in objective 24-hour cough frequency and 77% of treated patients achieving at least a 50% reduction, supporting a credible path to meaningful clinical and commercial success. The opportunity is also large and increasingly underappreciated, with management estimating a US TAM of more than $30B across IPF-related cough, non-IPF ILD, and RCC, while the company is the only therapy in active development for IPF chronic cough and faces limited competition across these indications. Strong IP, multiple de-risking Phase 2 studies, cash runway into 2030, and the removal of a major RCC competitor all improve its strategic value and help support a positive long-term outlook.

Trevi Therapeutics is exposed to a highly uncertain clinical and commercial profile because Haduvio remains an investigational therapy, and the recent failure of GSK’s camlipixant in RCC underscores how difficult chronic cough can be to treat despite prior enthusiasm. The outcome also suggests that single-pathway approaches may not reliably deliver durable efficacy across a heterogeneous patient population, which heightens concern that Haduvio may face the same class-wide limitations even if its mechanism differs. Although the cited valuation framework assigns an 80% probability of success in IPF-CC and 70% in RCC, the investment case still carries meaningful risks from competitive pressure, reimbursement uncertainty, regulatory and trial setbacks, capital needs, and operational dependence.